Skip to main content
. 2016 Jul 20;2(7):e1600692. doi: 10.1126/sciadv.1600692

Fig. 5. Ubiquitin variant validation.

Fig. 5

(A) Dose-response curve of USP21 activity inhibition by wild-type ubiquitin and the Ubv10 ubiquitin design. IC50 concentrations were evaluated as the ubiquitin concentration inhibiting USP21 activity by 50%. The Ubv10 dose-response curve has an IC50 value of 4.2 nM. (B) A strong correlation exists between the IC50 concentrations and the log-transformed deep sequencing counts.